title: Percutaneous tricuspid valve therapies: the new frontier.
abstract: Moderate-to-severe tricuspid regurgitation (TR) affects ∼1.6 million patients in the USA, of whom only 8000 undergo tricuspid surgery annually; this results in an extremely large number of untreated patients with significant TR. Therefore, there is a large unmet clinical need for patients with severe TR who are not referred for conventional surgery, mainly due to expected high surgical risk. Percutaneous procedures are an attractive alternative to surgery for patients deemed to be high-risk surgical candidates. Whereas over the past few years, the development and clinical use of percutaneous approaches to the aortic valve and mitral valve have been widespread, few data are available about the feasibility and the efficacy of the percutaneous tricuspid valve treatment. This review will explore the available technologies, which are today under evaluation and the preliminary clinical results.
authors.affiliation: Herz-Gefäss Chirurgie, UniversitätsSpital Zürich, University of Zürich, Rämistrasse 100, Zurich 8091, Switzerland.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Taramasso
authors.affiliation: Cardiac Surgery Department, San Raffaele University Hospital, Milan, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Pozzoli
authors.affiliation: Herz-Gefäss Chirurgie, UniversitätsSpital Zürich, University of Zürich, Rämistrasse 100, Zurich 8091, Switzerland.
authors.forename: Andrea
authors.initials: A
authors.lastname: Guidotti
authors.affiliation: Klinik für Kardiologie, UniversitätsSpital Zürich, University of Zürich, Zurich, Switzerland.
authors.forename: Fabian
authors.initials: F
authors.lastname: Nietlispach
authors.affiliation: Herz-Gefäss Chirurgie, UniversitätsSpital Zürich, University of Zürich, Rämistrasse 100, Zurich 8091, Switzerland.
authors.forename: Devdas T
authors.initials: DT
authors.lastname: Inderbitzin
authors.affiliation: Herz-Gefäss Chirurgie, UniversitätsSpital Zürich, University of Zürich, Rämistrasse 100, Zurich 8091, Switzerland.
authors.forename: Stefano
authors.initials: S
authors.lastname: Benussi
authors.affiliation: Cardiac Surgery Department, San Raffaele University Hospital, Milan, Italy.
authors.forename: Ottavio
authors.initials: O
authors.lastname: Alfieri
authors.affiliation: Herz-Gefäss Chirurgie, UniversitätsSpital Zürich, University of Zürich, Rämistrasse 100, Zurich 8091, Switzerland.
authors.forename: Francesco
authors.initials: F
authors.lastname: Maisano
mesh_terms: D020811:Biomedical Technology; D006328:Cardiac Catheterization / Q000379:methods*; D058385:Cardiac Valve Annuloplasty / Q000295:instrumentation / Q000379:methods; D018450:Disease Progression; D006801:Humans; D011379:Prognosis; D013525:Surgical Instruments; D014262:Tricuspid Valve Insufficiency / Q000209:etiology / Q000473:pathology / Q000601:surgery*
keywords: Functional tricuspid regurgitation; Transcatheter tricuspid therapy; Tricuspid valve